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Background: Urine exosomes are small vesicles exocytosed into the urine by all renal
epithelial cell types under normal physiologic and disease states. Urine exosomal proteins
may mirror disease specific proteome perturbations in kidney injury. Analysis methodolo-
gies for the exosomal fraction of the urinary proteome were developed for comparing the
urinary exosomal fraction versus unfractionated proteome for biomarker discovery.
Methods: Urine exosomes were isolated by centrifugal filtration of urine samples col-
lected from kidney transplant patients with and without acute rejection (AR), which were
biopsy matched. The proteomes of unfractionated whole urine (Uw) and urine exosomes
(Ue) underwent mass spectroscopy-based quantitative proteomics analysis.The proteome
data were analyzed for significant differential protein abundances in AR.
Results: A total of 1018 proteins were identified in Uw and 349 proteins in Ue. Two hun-
dred seventy-nine overlapped between the two urinary compartments and 70 proteins
were unique to the Ue compartment. Of 349 exosomal proteins identified from transplant
patients, 220 had not been previously identified in the normal Ue fraction. Eleven Ue pro-
teins, functionally involved in an inflammatory and stress response, were more abundant
in urine samples from patients with AR, three of which are exclusive to the Ue fraction.
Ue AR-specific biomarkers (1) were also detected in Uw, but since they were observed at
significantly lower abundances in Uw, they were not significant for AR in Uw.
Conclusion: A rapid urinary exosome isolation method and quantitative measurement of
enriched Ue proteins was applied. Perturbed proteins in the exosomal compartment of
urine collected from kidney transplant patients were specific to inflammatory responses,
and were not observed in the Ue fraction from normal healthy subjects. Ue-specific protein
alterations in renal disease provide potential mechanistic insights and offer a unique panel
of sensitive biomarkers for monitoring AR.
Keywords: urine exosomes, kidney transplant, acute renal allograft rejection, biomarkers, proteomics
INTRODUCTION
Exosomes are 50–90 nm vesicles secreted by a wide range of mam-
malian cell types as a consequence of fusion of multivesicular late
endosomes/lysosomes with the plasma membrane (2, 3). During
the construction of endosomes and intraluminal vesicles (ILVs),
specific membrane, and cytosolic proteins are incorporated and
secreted in the excretory pathway of exosomes. Therefore, exo-
somes from different cellular origins contain cell-type specific
components that mirror the biological function of the parent cell
as well as common molecules, which are needed for their struc-
ture and function (4). Recent evidence suggests that exosomes are
also involved in the modulation of immune function and dissem-
ination of several infectious cargos such as HIV. Exosomes can
also be involved in antigen presentation to T cells (5) and the
development of tolerance (6). DC-derived exosomes called dexo-
somes express high levels of functional MHC class-I and class-II
peptide complexes along with CD86 molecules (7). It was also
suggested that exosomal RNA could be transferred between cells
and represents a new mechanism of gene-based communication
between mammalian cells (8). These immune modulating and
cell to cell communication properties of exosomes indicate that
urine exosomes could be an advantageous source to study the
mechanisms of and discover useful biomarkers in variable kidney
diseases, including the study of various injury processes in kidney
transplantation.
The evolution of current mass spectrometry (MS)-based pro-
teomic approaches have contributed substantially to our under-
standing of the molecular characterization of urine proteins. How-
ever, one of the main hurdles for biomarker discovery with urine
proteomics is discerning proteins present at low levels from other
highly abundant proteins such as albumin and uromodulin. In
addition, the heterogeneity of urine protein added its complexity
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in urine proteomics. The origin of protein in proteinuric patients
could be one of the following; first, the filtrate of plasma pro-
tein through intact (overflow proteinuria) or damaged glomerular
basement membrane or podocyte (glomerulopathy), finally, excre-
tory vesicles (exosomes) or membrane-shed vesicles (microparti-
cles, also referred to as ectosomes) from kidney and uroepithelial
cells. In contrast to established proteomic approaches, subpro-
teome approaches which direct to study certain excretory vesicles
such as exosomes could be more informative for disease identifica-
tion and progression, because it could offer the simple way to get
rid of the most abundant protein from the unprocessed urine and
simplify the source of urine protein, especially for the proteinuric
patients.
Amid the early experiments to evaluate the route for the tubular
protein in urine, Pisitikun et al. isolated the exosomes from urine
with a differential ultracentrifugation method and confirmed the
expression of several apical transporter proteins, which originated
from renal tubules. More recently, this group analyzed the urine
exosomes using liquid chromatography coupled with tandem mass
spectrometry (LC-MS/MS) and identified 1132 proteins (2). Other
studies to find the biomarkers from specific small vesicles for
prostate and bladder cancers were also attempted (3, 4). Miranda
et al. also showed human urinary exosomes contained enough
mRNA for kidney specific genes (5). Nevertheless, the absence
of a standardized protocol for isolating exosomes from clinical
specimens and adequate normalization for timed collections are
hurdles to the clinical application of urine exosomes. However,
recent approaches, which use nanomembrane and microfilter cen-
trifugation to isolate exosome enriched fractions, suggested that
urine exosomes could be a reliable source for biomarker discovery
and incorporated into the clinical application (6, 7). We tested a
centrifugal filtration method to isolate exosomes from the urine
of kidney transplant recipients. Our result demonstrated that
the centrifugal filtration has advantage over the ultracentrifugal
method in its simple experimental setup, less time spent in exoso-
mal extraction, and identification of novel exosomal proteins that
were not reported by previously published works.
Data are lacking on the regulation of exosomes in physio-
logic stress and what differences occur in the urine exosomal
fraction under various pathologic conditions in kidney transplan-
tation. If the phenotype specific differences could be identified in
exosomes from the patients with different transplant-associated
renal injuries, subproteomics using exosomes could serve as good
complement to current proteomics and genomic approaches for
improving on our knowledge on the mechanism and monitoring
of renal injury.
In contrast to established proteomic approaches, subproteome
approaches which direct to study certain excretory vesicles such
as exosomes could be more informative for disease identification
and progression, because it could offer a method for biomarker
discovery in renal diseases without the confounding influence of
abundant proteins found in unprocessed urine.
In this study, we have undertaken a pilot study of 30 urinary
samples from renal transplant patients with biopsy proven AR and
20 urine samples from non-AR controls with other forms of renal
injuries such as BK nephropathy (BKVN) and chronic allograft
injury (CAI). The purpose of the study was to study if phenotype
specific differences could be identified in exosomal enrichment
fraction in urine from patients specific to biopsy confirmed acute
renal transplant rejection.
MATERIALS AND METHODS
STUDY POPULATION AND SAMPLES
A total of 30 mid-stream, second morning void urine samples
from kidney transplant patients that included non-acute rejection
(nAR; n= 20) and acute rejection (AR; n= 10) were selected from
a large and highly annotated biobank of urine samples collected
from pediatric and young adult recipients of kidney transplants
from 2000 to 2009 at Lucile Packard Children’s Hospital at Stan-
ford University. The bio-repository consisted of ~2000 banked
urine samples of which 770 were biopsy matched and collected
prior to any treatment intensification for clinical graft dysfunc-
tion.“Allograft injury”in this study was defined as a>20% increase
in serum creatinine from its previous steady-state baseline value
and an associated biopsy that was pathological. All biopsies were
blindly semi-quantitatively scored by a single pathologist using
the most recent Banff criteria for both acute and chronic injury
(1, 8–10). AR was defined at minimum, as per Banff Schema, a
tubulitis score ≥1 accompanied with an interstitial inflammation
score≥1, nAR patients were inclusive of patients with CAI and was
defined at minimum, as tubular atrophy score≥1 accompanied by
an interstitial fibrosis score≥1. Also, included were BKVN that was
defined by a demonstration of a positive blood BK viral load, graft
inflammation, and a positive immunohistochemical stain for the
polyoma virus. The patients included in this study were all on a
maintenance combination of tacrolimus, mycophenolic acid, and
were either on maintenance steroids or on a steroid avoidance
protocol (11). The study was approved by the Ethics Committee
of Stanford University Medical School and University of Califor-
nia San Francisco, and all patients/guardians provided informed
consent to participate in the research, in full adherence to the Dec-
laration of Helsinki. This study was approved by the Institutional
Review Board for Human Subjects Research at Pacific Northwest
National Laboratory in accordance with federal regulations.
URINE COLLECTION, INITIAL PROCESSING, AND STORAGE
We used standards recommended by human kidney and urine
proteome project (HKUPP) while collecting and processing sam-
ples that were applicable in the kidney transplant clinic. Second
morning, void, mid-stream urine samples (50–100 mL) were col-
lected in sterile containers and centrifuged at 2000× g for 20 min
at room temperature within 1 h of collection. The supernatant was
separated from the pellet containing any particulate matter includ-
ing cells and cell debris. The pH of the supernatant was adjusted
to 7.0 and stored at −80°C until further analysis. Prior to these
proposed studies, we established protocols that allowed for sta-
ble urine collection from multicenter clinical studies (12), where
delays in storage and processing can occur. With our protocols,
urine samples can be safely stored up to 1 h at room temperature
and up to 12 h at 4°C without significant protein degradation;
samples do not require addition of protease inhibitors to improve
sample integrity if stored at 4°C or −80°C within 72 h; and cen-
trifugal filtration was our optimal processing method. In order to
ensure minimum impact of freeze thaw cycles, we aliquoted urine
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samples into 10 mL aliquots (5–10 tubes per sample) prior to freez-
ing, to ensure that multiple assays can be done without multiple
freeze thaw cycles. Our assay utilized 10 mL starting urine so each
aliquot only needed to be thawed once for the experiments.
ISOLATION OF PROTEIN FROMWHOLE URINE
We followed previously published method that was developed in
the lab for urine protein isolation (13). Briefly, proteins were iso-
lated by using centrifugal filtration of the supernatant through
Amicon Ultra centrifugal filtration tubes (10,000 molecular weight
cutoff, Millipore, Bedford, MA, USA). The filter tube was initially
washed with 10 mL of 50 mM NH4HCO3 (pH 8.0) and discarded.
Then a 10 mL aliquot of urine was loaded into the device and cen-
trifuged for 20 min at 3000× g at 10°C, and the retentate was used
as protein extract for the whole urine.
ISOLATION OF URINE EXOSOMES
Exosome isolation by ultracentrifugation
Clarified urine (10 mL) was centrifuged at 200,000× g in a fixed
angle rotor (45Ti Beckman Instruments) for 110 min. The super-
natant was removed and the pellet washed with a large volume
of 1× phosphate buffered saline (PBS) and centrifuged again at
200,000× g for 110 min. The pellet was re-suspended in isolation
buffer (10 mM triethanolamine, 250 mM sucrose, pH 7.6) sup-
plemented with protease inhibitors (Complete Mini) and protein
concentration determined using a microBCA assay (Pierce).
Exosome isolation by nanomembrane concentrator
A 10 mL volume of urine was thawed and 12.5µL of Protease
Inhibitor Cocktail (Sigma-Aldrich P2714; prepared by adding one
vial to 5 mL nanopure water) per mL of urine was added. First, a
pool of urine samples was prepared by adding 0.5 mg urine crea-
tinine equivalent of urine (average urine volume 7.0± 2.3 mL) to
each pool of AR, BK, and CAI. An equal volume of 1× PBS buffer
was added to the urine. The urine was centrifuged at 2500× g
for 15 min at 25°C and transferred to high-speed tubes and then
centrifuged at 17,000× g for 30 min at 25°C. The supernatant
was transferred to a PBS buffer equilibrated nanomembrane con-
centrator (Vivaspin 20-PES 100,000 MWCO; VS2041) and cen-
trifuged at 3000× g at 25°C for 30 min. The filtrate was saved for
separate analysis. The retentate was washed with 20 mL of PBS
by centrifuging at 3000× g at 25°C for 20 min. The volume of
the retentate was adjusted to 200µL for downstream proteomic
analysis.
ONE-DIMENSIONAL, DENATURING, REDUCING ELECTROPHORESIS,
AND IMMUNOBLOTTING
Exosomal proteins (5–20µg) were separated using SDS-PAGE
on 4–12% NuPAGE gels (Invitrogen) at 200 V until the bro-
mophenol blue running dye migrated to the end of the gel using
Mark12 molecular weight standards (Life Technologies, Carlsbad,
CA, USA) and HK2 cell lysates or total urine protein as pos-
itive controls when possible. Proteins were electro-blotted and
probed using previously published methods (14). Primary anti-
body (0.2–1.0µg/mL) and secondary antibody (0.05–0.2µg/mL)
were dissolved in 5% w/v bovine serum albumin (Sigma-Aldrich)
in TTBS (Sigma-Aldrich). Secondary antibody conjugated with
horse-radish peroxidase (HRP) was visualized using the Pierce
SuperSignal® West Pico Chemiluminescent Substrate Kit. Mem-
branes were used to expose x-ray film and resulting images were
developed, scanned, and bands quantified.
TRANSMISSION ELECTRON MICROSCOPY OF WHOLE-MOUNTED
EXOSOMES
Exosome samples recovered in PBS were used for TEM characteri-
zation. Exosomes were pelleted by high-speed ultracentrifugation
at 200,000× g. PBS was removed by pipetting and 4% glutaralde-
hyde (Polysciences, Warrington, PA, USA) in PBS was layered
onto the exosomal pellet. Exosomal-protein glutaraldehyde-cross-
linking was allowed to proceed for 1 h. The cross-linked pellet
was submitted for TEM analysis. The cross-linked exosomes were
dehydrated in graded ethanol and flat-embedded in LX-112 epoxy
resin (Ladd Industries, Burlington, VT, USA). Selected areas were
mounted on blocks, ultra-thin sections (70–80 nm, silver-gray
interference color) were cut using a diamond knife (Diatome,
Fort Washington, PA, USA), and sections collected on copper
grids. The sections were stained with saturated solutions of uranyl
acetate, rinsed and submitted for imaging using a Philips CM10
transmission electron microscope operating at 60 kV.
QUANTITATIVE URINE EXOSOMAL PROTEOMICS BY USING iTRAQ AND
LC MS/MS
All peptide samples were assayed with bicinchoninic acid (BCA)
(Thermo Scientific, Rockford, IL, USA) to determine the protein
concentration. An equal mass of protein (20µg) was collected
from each sample and brought to a volume of 30µL using 0.5 M
triethylammonium bicarbonate (TEAB) (all chemicals purchased
from Sigma-Aldrich, St. Louis, MO, USA, unless otherwise stated).
2,2,2-Trifluoroethanol was added to the samples for a final concen-
tration of 50% TFE. The samples were sonicated in an ice-water
bath for 1 min and incubated at 60°C for 2 h with gentle shaking at
300 rpm. The samples were then reduced with 2 mM dithiothre-
itol (DTT) with incubation at 37°C for 1 h with gentle shaking at
300 rpm. Iodoacetamide was added to reach a final concentration
of 40 mM for alkylation and incubated in the dark at 37°C for 1 h
with constant shaking. The samples were then diluted sevenfold
using 0.5 M TEAB and digested with trypsin [50:1 protein:trypsin
(w/w)] (Promega, Madison, WI, USA) at 37°C for 3 h. To clean
the peptides, C-18 solid phase extraction (SPE) was performed
using Supelco Discovery columns with a Gilson GX-274 ASPEC™
system (Gilson Inc., Middleton, WI, USA) and eluted into a low-
protein binding 1.5 mL centrifuge tube. All samples were then
dried in a speed-vac to 15µL and assayed with BCA to determine
the peptide concentration.
8-plex iTRAQ labeling
The pH of each sample was measured and brought to ~pH 8 using
1 M TEAB. Each vial of 8-plex iTRAQ reagent (AB Sciex, Framing-
ham, MA, USA) was brought to room temperature. The reagents
were pulse spun to ensure the contents were collected at the bot-
tom and 60µL of isoproponal was added to each reagent vial.
The reagents were thoroughly vortexed, spun down, and added
to the appropriate sample. The reagent vials were rinsed with an
additional 10µL of isopropanol and added to the samples.
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The iTRAQ reagents with 8 channels 114–121 were used to label
2 pooled AR samples with each split into 2 as duplicates, 2 BKV,
and 2 CAI, respectively, for each 8-plex iTRAQ experiment. Three
8-plex experiments were performed for the 24 pools from the 4
phenotypes. For the labeling reaction, the pH was above 7.8 and
the organic concentration was at least 60% (v/v). Each sample was
vortexed and spun down to incubate at room temperature for 2 h
at which time 100µL of nanopure water were added to hydrolyze
the sample and incubated for an additional 30 min. The samples
were partially dried down in a speed-vac to remove the organic
solvent and then pooled together and dried down to a volume of
~100µL. An SPE C18 OMIX tip (Agilent, Santa Clara, CA, USA)
was used to clean the final sample for 2D-LC-MS/MS analysis.
2D-LC-MS/MS analysis
The final 8-plex iTRAQ-labeled sample was subjected to 2D-LC-
MS/MS analysis (15). The 2D-LC system was custom-built
using two Agilent 1200 nanoflow pumps and one 1200 cap-
illary pump (Agilent Technologies). Use of dual trapping and
reversed-phase columns allowed for parallel event coordina-
tion, allowing for fraction trapping and washing offline while
analytical separation occurred on the other reversed-phase col-
umn. Columns were manufactured in-house by slurry packing
media into fused silica (Polymicro Technologies Inc.) using a
1 cm sol-gel frit for media retention. First-dimension SCX col-
umn: 5µm PolySULFOETHYL-A (PolyLC Inc.), 15 cm× 360µm
od× 150µm id. Trapping columns: 5µm Jupiter C18 (Phe-
nomenex), 4 cm× 360µm od× 150µm id. Second-dimension
reversed-phase columns: 3µm Jupiter C18 (Phenomenex),
35 cm× 360µm od× 75µm id. Mobile phases consisted of
0.1 mM NaH2PO4 (A) and 0.3 M NaH2PO4 (B) for the first-
dimension column and 0.1% formic acid in water (A) and 0.1%
formic acid ACN (B) for the second-dimension column. The
SCX separation provided 15 fractions for the second-dimension
reversed-phase gradient nanoLC-MS/MS with 20µL for each
fraction.
Mass spectrometry analysis was performed on a Thermo Fisher
Scientific LTQ-Orbitrap Velos MS (San Jose, CA, USA) using a
150µm od× 20µm id chemically etched fused-silica electrospray
emitter (16). The SCX separation for 15 fractions was performed
stepwise, each step taking 20 min. Each fraction was trapped on
C18 material and washed for 50 min using the second-dimension
mobile phase A. The gradient was then started and 15 min later
acquisition was started and continued for 100 min for each frac-
tion. The heated capillary temperature and spray voltage were
350°C and 2.2 kV, respectively. Full MS spectra were recorded at a
resolution of 30,000 (for ions at m/z 400) over the range of m/z
400–2000 with an automated gain control (AGC) value of 1e6.
MS/MS was performed in the data-dependent mode with an AGC
target value of 3e4. The ten most abundant parent ions, excluding
single charge states, were selected for MS/MS using high-energy
collisional dissociation (HCD) with a normalized collision energy
setting of 40%. A dynamic exclusion time of 45 s was used.
STATISTICAL ANALYSIS
A fold change over the global normal was calculated for each pro-
tein in the soluble and exosomal fractions. Two tailed unpaired
t -tests were performed with SPSS software to determine the
significance of differences in fold change over global normal
between Uw and Ue compartments and differences in fold change
over the global normal between AR and no AR in the exosomal
fraction.
RESULTS
PATIENT DEMOGRAPHICS
A total of 30 urine samples were collected from AR (n= 10)
and nAR (n= 20) patients. In the AR population, at time of
sample collection, age ranged from 1.9 to 19.4 years of age
(mean= 14.5 years), 40% were female, 70% received deceased
donor transplants, 30% were living related donors, serum crea-
tinine ranged from 0.2 to 1.8 mg/dL (mean= 1.15 mg/dL) with a
calculated creatinine clearance (by the Schwartz equation) of 63–
206 mL/min/1.73 m2 (mean= 95 mL/min/1.73 m2). Primary kid-
ney diseases included focal segmental glomerulosclerosis (FSGS,
30%), reflux nephropathy/obstructive uropathy (20%), dysplasia
(10%), Alport’s syndrome (10%), lupus nephritis (10%), and 20%
were unknown. In the nAR population, at time of sample popula-
tion, age ranged from 1.7 to 18.7 years of age (mean= 12.1 years)
30% were female, 50% were deceased donors, and 50% were living
related donor transplants, serum creatinine at time of collection
ranged between 0.3 and 3.5 mg/dL (mean= 1.2 mg/dL) with a
calculated creatinine clearance range of 20–167 mL/min/1.73 m2
(mean= 89 mL/min/1.73 m2). Primary kidney diseases included
reflux nephropathy/obstructive uropathy (25%), unknown (20%),
FSGS (10%), 1 patient had both reflux and FSGS, dysplasia (10%),
vasculitis (10%), dysplasia (10%), nephrotic syndrome (10%),
and the remainder with, Alport’s syndrome, cortical necrosis, and
non-focal glomerulosclerosis.
URINE EXOSOME ISOLATION BY CENTRIFUGAL FILTRATION
Several exosomal extraction methods have been reported previ-
ously and included ultracentrifugation (2, 17, 18), nanomembrane
concentrator (6), and immunoisolation (19, 20). We tested two
methods that used ultracentrifugation and nanomembrane con-
centrator for this study. When we used 10 mL urine from three
different urine samples, the ultracentrifugation method did not
provide sufficient exosome protein extract (16± 9µg/mL raw
urine) for Western blot analysis (data not shown). Applying the
nanomembrane concentrator method to isolate urine exosomes,
did not require ultracentrifugation and provided much better exo-
somal yield in terms of total protein (678± 93µg/mL raw urine)
from the same set of three urine samples. The 100 kDa centrifu-
gal concentrators were used to isolate urine exosomes that could
be analyzed to verify for exosomal extract by Western blot and
electron microscopy (Figure 1). Programed Cell Death 6 Inter-
acting Protein (ALIX), Tumor Susceptibility 101 (TSG101), and
Aquaporin (AQP) were selected as markers for exosome vesicles
(17, 21) for the Western blot. The enriched exosomal extract was
tested for both the filtrate and the retentate fraction from the con-
centrator (Figure 1A). As demonstrated by electron micrograph
(EM) in Figure 1B, the exosomal extract contained exosomal vesi-
cles. This method was performed with urine at room temperature
that helped in minimizing the formation of Tamm–Horsfall pro-
tein aggregates that have been reported to be a major challenge
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FIGURE 1 | Confirmation of isolation of exosomal vesicles from human
urine. (A) Western blot demonstrated significant enrichment of exosomal
marker proteins in the retentate fraction. From the image analysis, there was
more retention of intact protein in the urine with added protease inhibitors
than without added protease inhibitors. (B) Electron micrograph (EM) of
isolated exosomes in the exosome extract.
when using ultracentrifugation which needs to be carried out at
4° C (22).
DETECTION OF NOVEL EXOSOMAL PROTEINS IN ACUTE REJECTION:
EXPANSION OF THE URINE EXOSOME DATABASE
2D-LC-MS/MS analyses of urine exosome samples resulted in
the identification of a total of 349 proteins in the exosomal
extract of which 343 proteins were identified in all injury phe-
notypes (Table S1 in Supplementary Material). We performed
gene ontology (GO) analysis which revealed that these pro-
teins were enriched in a number of biological pathways such
as platelet degranulation (p-value= 8.07e-4) and activation (p-
value= 7.39e-3), humoral immune response (p-value= 1.099e-
9), complement activation (p-value= 2.410–9), and response
to stress (p-value= 1.06e-4). GO molecular functions enriched
are lipid transport (p-value= 1.979e-3), lipoprotein binding (p-
value= 3.579e-4), and antioxidant activity (p-value= 5.049e-3).
The cellular components enriched included blood extracellu-
lar components (p-value= 2.820e-21), cell surface components
(p-value= 1.578e-8), blood mircoparticle (p-value= 2.769e-8),
secretory granule lumen (p-value= 4.520e-8), and cytoplasmic
membrane-bounded vesicle lumen (p-value= 7.849e-8). Evalua-
tion of public domain data for urine proteins previously described
in the Ue fraction of healthy subject control urine in both the
ExoCarta database and published literature (14, 23) revealed that
220/349 Ue proteins in kidney transplant patients had not been
previously identified in the healthy Ue fraction, indicative of
unique Ue proteins in kidney transplant recipients. When we
compared the 349 proteins to those previously identified in the
whole urine proteome data set (13), 70 are unique to the exoso-
mal fraction and 59 of these exclusive Ue proteins had not been
previously identified (Figure 2). They mainly enriched for bio-
logical pathways related to cell mediated immunity and response
to stress. The most significant molecular function was structural
molecule activity and their cellular components were mainly extra-
cellular or vesicle components. Twenty-five percent (18) of the
proteins exclusive to the exosomal fraction were enriched for their
higher expression in the renal cortex, based on our previous stud-
ies (24). High abundance urinary proteins, such as albumin and
FIGURE 2 | Relationship of total urine exosomal proteins (Ue), urine
exosomal proteins specific to acute rejection (AR) when compared to
soluble proteins in whole urine (Uw) and urine exosomal proteins
previously published in literature (previously identified). We identified
59 novel urinary exosomal proteins that are exclusive to the exosomal
fraction, including 3 (CLCA1, PROS1, and KIAA053) of which demonstrated
an increase fold change in the AR samples only. Venn diagram created with
VENNY (25).
tubulin, were not enriched in high abundance in the Ue fraction
(Figure 3).
IDENTIFICATION OF AR-SPECIFIC URINE EXOSOMAL PROTEINS
We quantitatively compared the abundance of the exosomal
proteins in the AR urine to the exosomal proteins in the
nAR urine using iTRAQ reagents. Eleven proteins namely
Alpha-2-macroglobulin (A2M), Apolipoprotein A-II (APOA2),
Apolipoprotein M (APOM), CD5 antigen-like (CD5L), calcium-
activated chloride channel regulator-1 (CLCA1), fibrinogen alpha
chain (FGA), fibrinogen beta chain (FGB), immunoglobulin-
mu chain C region (IGHM), defensin-5 (DEFA5), vitamin K-
dependent protein S (PROS1), and protein KIAA0753(KIAA0753)
were found to be increased in the exosomal fraction and signifi-
cantly increased in the AR population (Figure 4; Table 1). Three
of these proteins, calcium-activated chloride channel regulator 1,
Protein S, and KIAA0753 were found exclusively in the exoso-
mal fraction. They enriched for GO biological pathways such as
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platelet degranulation (p-value= 1.130e-8) and processes related
to lipoprotein assembly and clearance (p-value= 1.130e-8). We
performed two tailed t -tests of these proteins between Ue and
Uw as well as AR and nAR. In the AR and nAR comparisons,
DEFA5, a protein involved in the innate immune response, had
FIGURE 3 | Common proteins (e.g., albumin and tubulin) are not found
in abundance in the exosomal fraction. Our findings show that the fold
change of albumin and tubulin are much lower in the exosomal fraction than
soluble fraction of urine.
the greatest significant increase in AR (4.89± 0.23, p= 3.3e-5),
however, the difference in fold change in the Ue versus the Uw
compartment was not significant. CLCA1 had the least significant
increase in AR (p= 0.052). Six urine exosomal proteins were pre-
viously unidentified. APOM is a component of kidney epithelial
cells and has been previously linked to renal injury (26) but had
not been previously identified as a urine exosomal protein. In our
studies, we found it to be significantly increased in the exosomal
fraction (p= 0.022, CI= 1.15–2.88) and significantly increased in
the AR population (p= 0.001, CI= 1.64–3.22).Three novel urine
exosomal proteins, CLCA1, PROS1, and KIAA0753, were exclu-
sively found in the AR population of renal transplants. CLCA1
is a 100 kDa secreted membrane associated human protein typ-
ically found in mucus producing goblet cells. It is involved in
mediating calcium-activated chloride conductance (27). There is
evidence that it is involved in the regulation of tissue inflammation
in the innate immune response (28). PROS1 codes for the 75 kDa
secreted human Protein S anticoagulant, which is a co-factor to
activated protein C and is involved in the regulation of the coagula-
tion cascade by degrading Factors Va and VIIIa. Thus, it is involved
in blood coagulation and is associated with extracellular vesicles.
Based on information from GeneCard, KIAA0753 encodes for a
protein involved in ubiquination and protein degradation. Eight
Ue AR-specific markers are detected in Uw, but as they are at
much lower abundance levels in Uw, they are not significant for
AR in Uw.
In this study, urinary neutrophil gelatinase-associated lipocalin
(NGAL), which is a well-known urinary marker of kidney injury
(29) and graft dysfunction (30), was not identified despite the
fact that it has been reported to be detected in urine exosomes by
ELISA (31) and also by us in the mass spectrometric analysis of
soluble proteins in the urine (13). Another well-known urinary
protein, kidney injury molecule (KIM1) (32) was not identified
in this study but has been identified in the soluble urinary frac-
tion of urine collected from kidney transplantation patients (data
not shown). The absence of the well-known markers from our list
of 349 urine exosomal proteins is attributed to the fact that their
FIGURE 4 | (A) Urine from patients in the acute rejection population
enriched for eleven exosomal proteins with an increased fold change over
the whole urine fraction. All, except CLCA1, have significantly (p-values
<0.05) increased fold change in the Ue of AR when compared to Ue of
nAR. (B) They are also enriched in Ue over Uw. CLCA1, PROS1, and
KIAA0753 were detected in the exosomal fraction only, however, there is
only significantly increased enrichment (*) was observed for ApoM
(p=0.02).
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Table 1 | AR exosomal proteins.
Gene ID Description Function GO biological
processes
GO cellular
components
Average fold change:
(nd, not detected)
Fold change:
Ue (AR)-Ue (nAR)
Ue Uw p ∆ p
DEFA5 Defensin, alpha 5,
Paneth
cell-specific
Antimicrobial
activity possibly via
membrane
permeabilization
Antibacterial
response; humoral
and innate response
Extracellular; Golgi
lumen; cytoplasmic
vesicle
3.52 0.51 0.22 4.89 3.36e-05
KIAA0 753 109 kDa protein Uncharacterized
protein, associated
with protein
degradation
n/a Cytoplasm;
centrosome
2.50 nd n/a 3.03 0.055
CD5L CD5 molecule-like Regulates immune
system possibly via
apoptosis
Apoptosis; cellular
defense response
Extracellular 1.92 0.32 0.17 2.47 0.015
APOM Apolipoprotein M Binds various fatty
acids, most likely
involved in lipid
transport
Cholesterol
homeostasis,
transport, and
assembly; antioxidant
activity; response to
glucose
Extracellular;
HDL/VLDL
particles; plasma
membrane
1.82 −0.19 0.02 2.43 0.001
CLCA1 Calcium-activated
chloride channel
regulator 1
May mediate
calcium-activated
chloride
conductance;
associated with
immune response
and inflammation
Calcium ion and
chloride transport;
cellular response to
hypoxia
Extracellular;
plasma membrane;
microvillus
1.76 nd n/a 2.06 0.052
A2M Alpha-2-
macroglobulin
Inhibits all 4
classes of
proteases by
trapping
mechanism
Hemostasis/plate let
activation; negative
regulation of
complement; stem
cell differentiation
Cytosol;
extracellular;
platelet alpha
granule lumen
1.53 0.48 0.08 2.16 0.001
APOA2 Apolipoprotein
A-II
May stabilize HDL Acute inflammatory
response; cholesterol
homeostasis,
transport, and
assembly; host virus
interaction
Chylomicron;
endoplasmic
reticulum lumen;
extracellular;
HDL/VLDL particle
1.38 −0.47 0.28 2.83 0.001
PROS1 Vitamin
K-dependent
protein S
Activated protein C
co-factor, degrades
factors Va and VIIIa;
stimulates
fibrinolysis
Anticoagulation;
leukocyte migration
and immune response
Extracellular; Golgi
membrane
1.35 nd n/a 1.74 0.023
IGHM Immunoglobulin
heavy constant
mu
Constant region of
IgM, a soluble and
membrane bound
antibody
Immune response;
antibacterial immune
response
Extracellular;
plasma membrane
bound
1.34 0.22 0.41 1.95 0.006
(Continued)
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Table 1 | Continued
Gene ID Description Function GO biological
processes
GO cellular
components
Average fold change:
(nd, not detected)
Fold change:
Ue (AR)-Ue (nAR)
Ue Uw p ∆ p
FGA Fibrinogen alpha
chain
Component of
fibrinogen for
platelet
aggregation
Coagulation; platelet
activation and platelet
degranulation; signal
transduction
Extracellular;
plasma membrane;
extracellular
vesicles; fibrinogen
complex
1.3 0.73 0.06 1.81 0.006
FGB Fibrinogen beta
chain
Component of
fibrinogen for
platelet
aggregation
Coagulation; platelet
activation and
degranulation; signal
transduction
1.3 0.9 0.16 1.90 0.006
lower abundance in the urine and the dependence of unbiased
identification by a quantitative MS method, such as iTRAQ, on
protein abundance is biased toward proteins that are enriched in
the study sample (urine exosome) in this case.
DISCUSSION
Because of the potential of exosomes containing enriched candi-
date biomarkers for diseases there is a growing interest in exosome
isolation and investigation of its compositions. It has been shown
that exosomes are shed in urine and contain membrane bound
proteins and proteins involved in cell signaling, inflammation,
and originate from renal epithelial cells (2, 23). Previous studies
have shown that urine exosomes were enriched in innate immune
modulators, but there have not been studies that describe the
enrichment of exosomes in transplant injury compared to normal
in solid organ transplantation. Our Uexo extraction and purifica-
tion method is not only simple but is also readily transferrable to
other clinical labs.
We observe an enrichment of exosome specific proteins in
kidney transplant patients who have biopsy proven AR, and per-
turbation in the Ue fraction by disease resulted in a repertoire
very different from the Ue fraction in normal health. In fact, only
9% of the Ue proteins detected in healthy urine were noted in
the Ue fraction from patents with renal transplants, and most of
these overlapping Ue proteins are involved in vesicle-mediated
transport (p= 2.109e-14), regulatory mechanisms (2.109e-14),
and response to stress (p= 1.060e-13). In kidney transplantation,
the ischemic and alloimmune injury to the donor kidney resulted
in marked changes in the Ue fraction, with an enrichment of pro-
teins involved in inflammation, cell division, tissue repair, and the
immune response. AR creates an environment of inflammation
of the renal tubule (the tubulits injury in AR), interstitium, and
the vascular space and the altered response of the injured tubules
to these infiltrating cells is seen by a predominance of proteins
involved in cell repair (p= 0.037) and fibrosis (p= 0.03).
The orchestrated injury and its local response in transplant
rejection is highly specific and likely explains the almost com-
plete alteration of the Ue fraction in urine samples taken from
organ transplant patients versus normal healthy volunteers. The
highly specific nature of the perturbations of the Ue compart-
ment in disease, make the study of this space very attractive in
terms of studying disease and injury mechanism. Additionally, as
these altered protein fractions mirror the local organ injury, mon-
itoring for changes in the abundance of these proteins could be
tracked as sensitive disease and injury specific biomarkers. Our
studies indicate that the Ue-specific AR biomarkers in this pilot
study are highly specific for AR versus other types of transplant
injury, and can only be identified by Ue analysis due to their very
low abundance or even complete absence from similar analysis of
unfractionated whole urine.
Within this compartment, we identified proteins (CLCA1,
PROS1, and KIAA0753) that are exclusive to AR patients and have
not been previously identified in the available databases of healthy
urine exosomal proteins. Since these proteins are enriched in
inflammatory responses, they may serve as valuable useful mark-
ers of rejection. Also, within this compartment is ApoM, which
has been previously identified to in soluble urine and associ-
ated with kidney injury. We show that exosomal ApoM is more
abundant than soluble ApoM thus supporting that exosomal pro-
teins could serve as a more sensitive biomarker. Numerous studies,
including those originating from our group have shown that using
elevated creatinine and biopsy results to identify renal transplant
dysfunction and rejection is often a late finding (33–36). Further
studies are needed to evaluate if the Ue-specific proteins in AR, are
altered earlier in the course of rejection injury, and if their altered
detection, when altered, can predate a rise in the serum creatinine
providing the potential for early intervention and prompt injury
reversal.
In conclusion, in this report, we have optimized a rapid uri-
nary exosome isolation method and quantitative measurement of
enriched Ue proteins. Our observation from this study demon-
strated that proteins in the exosomal compartment of urine col-
lected from kidney transplant patients were specific to inflamma-
tory responses, which were different from normal healthy subjects.
However, the small sample size of the study and because of the
possibility of >100 kDa proteins isolation due to the cutoff size
of the nanomembrane concentrater, future studies with larger
sample size and further refinement in the exosomal method is
warranted.
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